Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
Alessandro Leonetti, Roberta Minari, Luca Boni, Letizia Gnetti, Michela Verzè, Luigi Ventura, L Musini, Michele Tognetto, Marcello Tiseo
Topics & Concepts
AlectinibMedicineClinical endpointOncologyInternal medicineAnaplastic lymphoma kinaseALK inhibitorLung cancerAdverse effectClinical trialNeoadjuvant therapyStage (stratigraphy)non-small cell lung cancer (NSCLC)CancerBreast cancerBiologyMalignant pleural effusionPaleontologyA549 cellLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and Biomarkers